Daisaku Yamada

Daisaku Yamada

Auto-generated profile, based on publicly available information

Daisaku Yamada

Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
YYYuki Yokota
Yuki Yokota
TNTakehiro Noda
Takehiro Noda
YOYuichiro Okumura
Yuichiro Okumura
SKShogo Kobayashi
Shogo Kobayashi
YIYoshifumi Iwagami
Yoshifumi Iwagami
HEHidetoshi Eguchi
Hidetoshi Eguchi
Hepatocellular carcinoma (HCC) is the second leading cause of cancer‐related death. High recurrence rates after curative resection and the lack of specific biomarkers for intrahepatic metastases are major clinical problems. Recently, exosomal microRNAs (miRNAs) have been reported to have a role in the formation of the pre‐metastatic niche and as promising biomarkers in patients with malignancy. Here we aimed to clarify the molecular mechanisms of intrahepatic metastasis and to identify a novel biomarker miRNA in patients with HCC. A highly intrahepatic metastatic cell line (HuH‐7M) was established by in vivo selection. HuH‐7M showed increased proliferative ability and suppression of apoptosis and anoikis. HuH‐7M and the parental cell (HuH‐7P) showed the similar expression of epithelial mesenchymal transition markers and cancer stem cell markers. In vivo, mice treated with exosomes derived from HuH‐7M showed increased tumorigenesis of liver metastases. Exosomes from HuH‐7M downregulated endothelial cell expression of vascular endothelial‐cadherin (VE‐cadherin) and zonula occludens‐1 (ZO‐1) in non‐cancerous regions of liver and increased the permeability of FITC‐dextran through the monolayer of endothelial cells. The miRNAs (miR‐638, miR‐663a, miR‐3648, and miR‐4258) could attenuate endothelial junction integrity by inhibiting VE‐cadherin and ZO‐1 expression. In patients with HCC, higher serum exosomal miR‐638 expression was associated with tumor recurrence. In conclusion, the miRNAs secreted from a highly metastatic cancer cell can promote vascular permeability via downregulation of endothelial expression of VE‐cadherin and ZO‐1. Serum exosomal miR‐638 expression holds potential for serving as a significant and independent prognostic marker in HCC. Supporting information

1 September 2019 in European Journal of Radiology
Verified
Journal Article
Closed access
ヒフヒデユキ フクイ
ヒデユキ フクイ
MHMasatoshi Hori
Masatoshi Hori
YFYasunari Fukuda
Yasunari Fukuda
HOHiromitsu Onishi
Hiromitsu Onishi
ANAtsushi Nakamoto
Atsushi Nakamoto
NTNoriyuki Tomiyama
Noriyuki Tomiyama

24 March 2022 in Cancer Science
Verified
Journal Article
Open access
YSYoshihiro Sakano
Yoshihiro Sakano
TNTakehiro Noda
Takehiro Noda
SKShogo Kobayashi
Shogo Kobayashi
KSKazuki Sasaki
Kazuki Sasaki
YIYoshifumi Iwagami
Yoshifumi Iwagami
HEHidetoshi Eguchi
Hidetoshi Eguchi
Tumor endothelial cells (TECs) promote tumor angiogenesis and regulate cytotoxic T cells in the tumor microenvironment. However, the roles of TECs for tumor‐infiltrating T‐cell in hepatocellular carcinoma (HCC) is still unknown. Here, we aimed to investigate how TECs influenced tumor growth and immune responses of HCC focusing on CD8+ T‐cell infiltration and exhaustion. First, TECs were isolated from subcutaneous HCC tumors with murine HCC cell lines (BNL‐T) with magnetic selection of CD31+ cells, and normal endothelial cells (NECs) were isolated from normal liver. Second, immunocompetent mice were injected with BNL‐T alone, BNL‐T + NECs, or BNL‐T + TECs for tumor formation, and the functions and exhaustion of tumor‐infiltrating CD8+ T cells were evaluated. The mice injected with BNL‐T + TEC showed rapid tumorigenesis and a decrease in the number of infiltrating CD8+ T cells. In addition, the percentage of CD8+ T‐cell exhaustion was significantly higher in tumors from the administration of BNL‐T + TEC. Third, the next‐generation sequencing on TECs was performed to identify mRNAs that might be a novel treatment target. The molecule of glycoprotein nonmetastatic melanoma protein B (GPNMB) was identified and the functions of GPNMB was analyzed by silencing of GPNMB expression using small interfering RNAs. The silencing of GPNMB expression in TECs induced the suppression of tumor growth and T‐cell exhaustion. In conclusion, TECs induced tumor‐infiltrating T‐cell exhaustion via GPNMB expression and GPNMB might be a novel therapeutic target in HCC.

18 April 2017 in Surgery Today
Verified
Journal Article
Closed access
PDF file
DYDaisaku Yamada
Daisaku Yamada
HEHidetoshi Eguchi
Hidetoshi Eguchi
TATadafumi Asaoka
Tadafumi Asaoka
HTHideo Tomihara
Hideo Tomihara
TNTakehiro Noda
Takehiro Noda
YDYuichiro Doki
Yuichiro Doki

17 December 2020 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
HAHirofumi Akita
Hirofumi Akita
HTHidenori Takahashi
Hidenori Takahashi
HEHidetoshi Eguchi
Hidetoshi Eguchi
KAKei Asukai
Kei Asukai
SHShinichiro Hasegawa
Shinichiro Hasegawa
MSMasato Sakon
Masato Sakon
Background: An accurate evaluation of neoadjuvant treatment is important to maximize the prognostic benefit of this strategy in each individual patient. The main aim of the present study is to investigate the difference between carbohydrate antigen 19‐9 and fluorine‐18 fluorodeoxyglucose positron emission tomography (FDG‐PET) in evaluating the response to neoadjuvant treatment for resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC) patients.Methods: Pancreatic ductal adenocarcinoma patients with positive standard uptake values (SUV) on FDG‐PET before neoadjuvant chemoradiotherapy (NACRT) were enrolled (n = 141). In all patients, CA19‐9 and FDG‐PET were evaluated before the initiation of and after the completion of NACRT. The statuses of CA19‐9 and FDG uptake alterations during NACRT were assessed in association with survival and tumor recurrence profiles.Results: A favorable response in each CA19‐9 and FDG‐PET was significantly related to better survival, respectively, than the unfavorable response (44.3% vs 19.5%, P < .001 and 45.8% vs 24.6%, P < .001). The status of CA19‐9 was significantly associated with the incidence of distant recurrence whereas the status of FDG‐PET was significantly associated with the incidence of local recurrence, and only patients with a favorable response in both CA19‐9 and PET statuses showed a significantly better survival than the others (5‐year survival: 56% vs 24%, P < .001), and those with unfavorable response in either of CA19‐9 or PET status showed similar poor survival to those with unfavorable in both (P = .164).Conclusion: CA19‐9 and PET evaluation provided oncologically different risk assessments in terms of tumor recurrence profile, and favorable response in both CA19‐9 and FDG‐PET were necessary to achieve prognostic benefit from NACRT.

26 August 2021 in Trials
Verified
Journal Article
Open access
PDF file
DYDaisaku Yamada
Daisaku Yamada
SKShogo Kobayashi
Shogo Kobayashi
HTHidenori Takahashi
Hidenori Takahashi
HAHirofumi Akita
Hirofumi Akita
TYTerumasa Yamada
Terumasa Yamada
HEHidetoshi Eguchi
Hidetoshi Eguchi
Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, and multimodal strategies, such as surgery plus neoadjuvant chemotherapy (NAC)/adjuvant chemotherapy, have been attempted to improve survival in patients with localized PDAC. To date, there is one prospective study providing evidence for the superiority of a neoadjuvant strategy over upfront surgery for localized PDAC. However, which NAC regimen is optimal remains unclear.Methods: A randomized, exploratory trial is performed to examine the clinical benefits of two chemotherapy regimens, gemcitabine plus S-1 (GS) and gemcitabine plus nab-paclitaxel (GA), as NAC for patients with planned PDAC resection. Patients are enrolled after the diagnosis of resectable or borderline resectable PDAC. They are randomly assigned to either NAC regimen. Adjuvant chemotherapy after curative resection is highly recommended for 6 months in both arms. The primary endpoint is tumor progression-free survival time, and secondary endpoints include the rate of curative resection, the completion rate of protocol therapy, the recurrence type, the overall survival time, and safety. The target sample size is set as at least 100.Discussion: This study is the first randomized phase II study comparing GS combination therapy with GA combination therapy as NAC for localized pancreatic cancer.Trial registration: UMIN Clinical Trials RegistryUMIN000021484. This trial began in April 2016.